Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | QDPR | P09417 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22306166 | 0.79 | ATM (0.34) | ALDH1A1L3MBTL1MAPK1SMN1; SMN2NCF1 | |
| SCHEMBL8966743 | 0.79 | ATM (0.34) | ALDH1A1L3MBTL1MAPK1SMN1; SMN2NCF1 | |
| SCHEMBL22306162 | 0.79 | ATM (0.34) | ALDH1A1L3MBTL1MAPK1SMN1; SMN2NCF1 | |
| SCHEMBL18388005 | 0.76 | — | — | |
| SCHEMBL16903337 | 0.76 | NCF1 (0.32) | NCF1KMT2A | |
| SCHEMBL16903340 | 0.75 | NCF1 (0.33) | NCF1KMT2A | |
| SCHEMBL18903236 | 0.71 | NCF1 (0.32) | NCF1 | |
| SCHEMBL26088608 | 0.68 | — | — | |
| SCHEMBL13625216 | 0.68 | — | — | |
| SCHEMBL24734693 | 0.68 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1MAPK1SMN1; SMN2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196720-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-9181288-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150197533-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | ALDH1A1 2038/4885L3MBTL1 4465/4885OPRD1 2937/4885 |
| US-20150197533-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | ALDH1A1 2038/4885L3MBTL1 4465/4885OPRD1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.